Nyrada Inc (NYR)
20mins delayed
Movement
1 Year Return
Nyrada Inc Chart
| Share price | |
| Last | |
| Change | |
| Volume | |
| Turnover | |
| Market Cap | $19.09 million |
| Today's Movement | |
| Prev. Close | |
| Open | |
| Day Range | - |
| VWAP | |
| Historical Stats | |
| 52w Range | - |
| 4w Avg Volume | |
| 4w Avg Turnover | |
| (delayed) | |
NYR Statistics
04 December
1,712 / 2,258
ASX Size Rank
1yr Return
vs Sector (1yr)
-5.25%
vs ASX 200 (1yr)
+7.12%
$19.09 million
Market Cap
Share Issue
76.36 million
All Ords (%)
N/A
Short Sold
0%
Current Fundamentals
04 December
N/A
PE Ratio
EPS ($)
-
Earnings Yield
-
NTA ($)
-
0.00%
Dividend Yield
DPS ($)
-
Gross Div. Yield
-
Gross DPS ($)
-
Company Overview
Nyrada Inc (NYR) is a preclinical stage, drug development company. The Company specialises in the development of novel small molecule drugs pertaining to the underlying pathological processes involved in cardiovascular, neurodegenerative and chronic inflammatory diseases. It focuses on areas of substantial unmet clinical need and has identified drug candidates with therapeutic and commercial potential, where few if any, effective or well-tolerated therapies exist. It currently has three wholly-owned drug programs:
Upcoming Calendar
| 23 Feb 2021 | Report (Interim) |
| 30 Aug 2021 | Report (Prelim) |
| 7 Sep 2021 | Report (Annual) |
Dividend History
| Ex-Date | Amount | Franking | Type | Payable |
|---|---|---|---|---|
| No dividends paid in the last 5 years | ||||
See Upcoming Dividends for all ASX companies.
Announcements
| Date | Heading | Pages | File Size | Time |
|---|---|---|---|---|
Announcements provided by
Broker Consensus
The buy, hold and sell recommendations from Australian stockbroking firms are combined to form a "broker consensus". See the Consensus Data posts for more information.
NYR is not covered by a major broker,
or data from most recent compilation was omitted due
to not meeting QA guidelines.
Directors & Management
| Name | Title | Since | Bio |
|---|---|---|---|
| Mr Peter Ashley Marks | Non-Executive Director | Aug 2017 |
|
| Dr Ian Edward Dixon | Founder, Non-Executive Director | Sep 2020 |
|
| Mr John Alexander Moore | Non-Executive Chairman, Non-Executive Director | Jun 2019 |
|
| Mr Ruediger Weseloh | Non-Executive Director | Jun 2019 |
|
| Mr Christopher Cox | Non-Executive Director | Nov 2019 |
|
| Mr Marcus Frampton | Non-Executive Director | Jun 2019 |
|
| Mr David Franks | Company Secretary | - | |
| Mr James Bonnar | Chief Executive Officer | - |
Director Transactions
NYR directors must report any change in shareholding to the ASX within 5 business days.
See Director Transactions for all ASX companies.
| Date | Director | Type | Amount | Price | Value | Notes |
|---|---|---|---|---|---|---|
| 10/09/20 | John Moore | Buy | +32,500 | $0.210 | $6,825 | On-market trade. |
| 23/04/20 | John Moore | Buy | +35,000 | $0.168 | $5,882 | On-market trade. |
Shareholder Distribution
| Holding Size | 1 - 1,000 | 1,001 - 5,000 | 5,001 - 10,000 | 10,001 - 100,000 | 100,001 and over | Total Shareholders |
|---|---|---|---|---|---|---|
| No. of Shareholders | 10 | 212 | 162 | 544 | 107 | 1,035 |
Top 20 Shareholders
| Name | Shares | Capital |
|---|---|---|
| Noxopharm Limited | 33,373,245 | 30.51% |
| Altnia Holding Pty Ltd | 9,921,725 | 9.07% |
| Goodridge Nominees Pty Ltd |
4,600,000 | 4.21% |
| Goodridge Foundation Pty Ltd |
3,450,000 | 3.15% |
| Colin Housely & Freda Housely |
1,863,725 | 1.70% |
| Sunset Capital Management Pty Ltd |
1,500,000 | 1.37% |
| Kohen Enterprises Pty Ltd | 1,335,000 | 1.22% |
| John W King Nominees Pty Ltd | 1,242,483 | 1.14% |
| Goodridge Nominees Pty Ltd |
1,212,416 | 1.11% |
| Goodridge Foundation Pty Ltd |
1,212,416 | 1.11% |
| Rhlc Pty Limited |
1,000,000 | 0.91% |
| Mr Michael Francis Mcmahon & Mrs Susan Lesley Mcmahon |
885,000 | 0.81% |
| Mr Graham Arthur Robinson | 878,888 | 0.80% |
| Symphony Capital Holdings Llc | 800,000 | 0.73% |
| Mr Anthony John Locantro | 644,000 | 0.59% |
| Lawsam Pty Ltd | 621,241 | 0.57% |
| Baywick Pty Ltd |
621,241 | 0.57% |
| Mr John Gardner | 500,000 | 0.46% |
| Phytose Corporation Pty Limited |
466,551 | 0.43% |
| Mr John Sellers | 448,496 | 0.41% |
| Carda Pty Ltd |
405,000 | 0.37% |
| J P Morgan Nominees Australia Pty Limited | 360,500 | 0.33% |
| All other shareholders | 38.43 % | |
The Top 20 Shareholders of NYR hold 61.57% of shares on issue.
NYR Share Price History
| Date | Close | Change | % Change | Open | High | Low | Volume | Turnover |
|---|---|---|---|---|---|---|---|---|
NYR Historical Data
Download up to 20 years of share price history.
| Year | Closing Price (30 June) | Last Trade |
|---|---|---|
| 2020 | $0.175 | 30 June |
Offical data as published by ASX. See more Data Downloads.
Company Details
Principal Activity: Development of therapeutic treatments for cardiovascular, neurological and inflammatory/autoimmune diseases, testing and optimization of novel drug candidates while building on the Company's patent portfolio.
Incorporated: --
1209 Orange St
Wilmington Delaware USA 19801
All data on this page is supplied by the ASX, Morningstar and Market Index. Read the disclaimer.